In the present investigation ethyl 2-(4-carboxyphenylazo)acetoacetate 1 on condensation with various aromatic aldehydes in ethanolic NaOH solution yielded the corresponding chalcones 2a-j. These chalcones were further reacted with urea in the presence of base in ethanol, which led to the formation of pyrimidine derivatives 3a-j. The newly synthesized heterocyles were characterized on the basis of their chemical properties and spectroscopic data. All newly synthesized compounds were evaluated for their antimycobacterial activities against Mycobacterium tuberculosis H 37 Rv.
Introduction
Tuberculosis (TB) is by far the most frequently encountered mycobacterial disease in the world. 1 Although its incidence has diminished significantly in the industrially more developed countries; it remains a major public health problem in most of the developing nations. Tuberculosis is still the single largest infection having a high mortality rate and 0.1 to 0.3 percent of the population become infected each year in the developed countries. This year, 2 million people may develop the disease and 30 million may die worldwide (as per a WHO report). It is commonly known that Mycobacterium tuberculosis has developed resistance to the majority of the existing drugs. However, powerful new anti-TB drugs with new mechanisms of action have not been developed in the last forty years. In the developing countries, the annual infection rate is 20-50 times greater than in the developed countries and its high level shows little or no downward trend. It is expected that development of new effective anti-TB drugs will bring various outcomes viz: shortening the total duration of therapy, reducing the total expenditure and treatment of multiple drug resistant tuberculosis (MDR-TB) by single dosage regiment. 2, 3 In pursuit of achieving this goal, our research efforts are focused on the development of novel structural moieties having antimycobacterial properties. 4, 5 Chalcones have various biological activities such as cytotoxic, 5 12, 13 as well as synthetic drugs. 14 Pyrimidines are associated with various therapeutic activities e.g.,
anti-HIV, 15 anti-tubercular, 16 antitumor, 17 antineoplastic, 18 anti-inflammatory, 19 diuretic, 20 antimalaria, 21 cardiovascular. 22 To the best of our knowledge, there has been no previous reports of analogous pyrimidines and parent chalcones as antituberculosis agents. However, there are numerous examples of nitrogen containing heterocycles being used to treat TB, for example Clofazimine, Isoniazid and Pyrazinamide. These compounds provide structural precedence that our chalcone and pyrimidine analogues may lead to the generation of novel anti-TB therapeutics.
Herein the synthesis and in vitro antimycobacterial activity of novel chalcone and pyrimidine derivatives are described.
Results and Discussion

Chemistry
The synthesis of chalcone and pyrimidine derivatives was performed following the steps shown in Scheme-1. In the initial step, chalcones (2a-j) were synthesized by condensing 2-(4-carboxyphenylazo)acetoacetate 23 1 with appropriate arometic aldehydes in dilute ethanolic sodium hydroxide solution at room temperature. The compounds (3a-j) were synthesized by reacting the appropriate chalcone with urea and potassium hydroxide in ethanol. 
Scheme 1
The possible mechanism involved in the formation of dihydropyrimidine derivatives (3a-j) from the respective chalcones (2a-j) is shown below.
Biological screening Microbiology
The in vitro activities of the synthesized compounds (2a-j & 3a-j) for tuberculosis inhibition against the Mycobacterium tuberculosis H 37 Rv (ATCC27294) strain were performed using the micro plate alamar blue assay (MABA) 24 method at TAACF. Compounds exhibiting fluorescence are tested in a BACTEC-460 radiometric system 25, 26 and/or broth micro dilution assay. The activities are expressed as minimum inhibitory concentration (MIC, µg/mL) and are summarized in Table 1 . Compounds demonstrating at least 90 % inhibition were re-tested at lower concentrations to determine the actual MIC, a value defined as the lowest concentration inhibiting ≈ 90% of the inoculums relative to the control.
Antimycobacterial activity
Twenty compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H 37 Rv using a BACTEC-460 radiometric system. Among the chalcones 2a-j and pyrimidines 3a-j, compounds 3d, 3e and 3g produced the highest efficacy and exhibited >90% inhibition at 6.25 ≈ µg/ml in the primary screen (Table 1) . Compounds 2a-j, 3a-c, 3f and 3h-j exhibited >90% inhibition against Mycobacterium tuberculosis at 6.25 µg/mL (Table 1) . These antimycobacterial data clearly indicated that the presence of 2-nitro, 3-nitro and 4-methoxy substitution on chalcone produced remarkable improvements in antitubercular activity. 
Conclusions
In conclusion, a new class of chalcone and pyrimidines derivatives were synthesized and evaluated as antitubercular agents. The newly synthesized heterocycles exhibited promising antitubercular activities against Mycobacterium tuberculosis. These results makes novel chalcone and pyrimidine derivatives interesting lead molecules for further synthetic and biological evaluation. It can be concluded that this class of compounds certainly holds great promise towards the pursuit to discover novel classes of antimycobacterial agents. Further studies to acquire more information concerning structure-activity relationships are in progress.
Experimental Section
General Procedures. 
General procedure for the synthesis of 3-(4'-aryl)-1-[(4)-carboxyphenylazomet hyl]-2-propene-1-one (2a-j)
To a mixture of ethyl 2-(4-carboxyphenylazo)acetoacetate (1) (0.01 mol) and the appropriate aldehyde (0.01 mol) in oxygen-free ethanol was added a solution of sodium hydroxide in oxygen-free distilled water with constant stirring of the reaction flask. The reaction mixture was stirred for 24 hours on a magnetic stirrer and poured on to crushed ice. The solid mass that separated out was filtered, washed with water and crystallized from ethanol to furnish the desired product (2a-j) as yellow crystals. 
3-(4'-Phenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2a
3-(4'-Methoxyphenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2g
